Medscape12d
Pheochromocytoma: Recommendations for Clinical Practice from the First International Symposium
The First International Symposium on Pheochromocytoma ... localization, genetics, and treatment. Measurement of plasma or urinary fractionated metanephrines, the most accurate screening approach ...
Nature3y
The first FDA approved treatment for ultra-rare endocrine tumors
Fortunately, there is now an effective treatment available for patients with unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma (PPGL). A recent review in Cancers from ...
Hosted on MSN16d
MSD wins FDA priority review for Welireg in rare endocrine cancer
The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...
Monthly Prescribing Reference17d
Belzutifan Gets Priority Review for Advanced Pheochromocytoma and Paraganglioma
for belzutifan for the treatment of adult and pediatric patients aged 12 years and older with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). According to Merck, the ...
Cure Today14d
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Merck's Welireg oral cancer drug gets FDA priority review
Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.
Pharmabiz16d
US FDA grants priority review status to Merck’s sNDA for Welireg to treat patients with advanced pheochromocytoma and paraganglioma
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
Targeted Oncology6d
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Pharm Exec16d
FDA Grants Priority Review to Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
Endocrinology Advisor1d
January 2025 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
The Pharma Letter15d
Merck’s Welireg sNDA accepted for priority review in PPGL
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for Welireg (belzutifan), Merck & Co’s oral hypoxia-inducible factor-2 alpha ...
Monthly Prescribing Reference7d
January 2025 Recap: Drug Pipeline Updates
Hypoxia-inducible factor inhibitor Treatment of adult and pediatric patients aged 12 years and older with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma. sNDA accepted ...